Hefei Lifeon Pharmaceutical Co., Ltd. (SHE:003020)
China
· Delayed Price · Currency is CNY 22.89
+0.29 (1.28%)
At close: Apr 29, 2026
SHE:003020 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,554 | 1,488 | 1,887 | 2,570 | 2,261 | Upgrade
|
| Other Revenue | - | 30.32 | 14.25 | 8.86 | 11.77 | Upgrade
|
| Revenue | 1,554 | 1,518 | 1,901 | 2,579 | 2,273 | Upgrade
|
| Revenue Growth (YoY) | 2.33% | -20.11% | -26.31% | 13.46% | 20.01% | Upgrade
|
| Cost of Revenue | 550.81 | 479.46 | 932.11 | 1,619 | 1,369 | Upgrade
|
| Gross Profit | 1,003 | 1,039 | 968.68 | 960.28 | 904.36 | Upgrade
|
| Selling, General & Admin | 724.35 | 772.94 | 659.7 | 675.31 | 650.1 | Upgrade
|
| Research & Development | 110.78 | 91.78 | 84.96 | 73.8 | 65.86 | Upgrade
|
| Other Operating Expenses | 1.57 | 19.31 | 14.97 | 15.96 | 16.06 | Upgrade
|
| Operating Expenses | 836.69 | 887.09 | 762.82 | 765.5 | 731.99 | Upgrade
|
| Operating Income | 166.3 | 151.94 | 205.85 | 194.78 | 172.36 | Upgrade
|
| Interest Expense | - | -1.92 | -1.28 | -0.89 | -1.36 | Upgrade
|
| Interest & Investment Income | 27.72 | 13.62 | 32.14 | 36.68 | 14.58 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.01 | 0.04 | 0.4 | -0.18 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.79 | -0.75 | 0.92 | -0.17 | -0.34 | Upgrade
|
| EBT Excluding Unusual Items | 192.23 | 162.9 | 237.67 | 230.81 | 185.06 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.15 | 1.6 | 0.32 | -0.04 | -0.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | 0.02 | - | -2.54 | -0.03 | Upgrade
|
| Asset Writedown | -10.58 | -6.43 | -0.12 | -0.39 | -0.27 | Upgrade
|
| Other Unusual Items | - | 13.72 | 19.55 | 11.98 | 10.09 | Upgrade
|
| Pretax Income | 181.8 | 171.82 | 257.42 | 239.82 | 194.84 | Upgrade
|
| Income Tax Expense | 18.24 | 19.34 | 23.53 | 30.57 | 22.61 | Upgrade
|
| Earnings From Continuing Operations | 163.55 | 152.48 | 233.88 | 209.25 | 172.23 | Upgrade
|
| Minority Interest in Earnings | 1.64 | 8.12 | -7.21 | - | - | Upgrade
|
| Net Income | 165.2 | 160.6 | 226.67 | 209.25 | 172.23 | Upgrade
|
| Net Income to Common | 165.2 | 160.6 | 226.67 | 209.25 | 172.23 | Upgrade
|
| Net Income Growth | 2.86% | -29.15% | 8.33% | 21.50% | 27.47% | Upgrade
|
| Shares Outstanding (Basic) | 190 | 191 | 192 | 189 | 188 | Upgrade
|
| Shares Outstanding (Diluted) | 190 | 191 | 192 | 189 | 188 | Upgrade
|
| Shares Change (YoY) | -0.68% | -0.47% | 1.75% | 0.49% | 33.01% | Upgrade
|
| EPS (Basic) | 0.87 | 0.84 | 1.18 | 1.11 | 0.92 | Upgrade
|
| EPS (Diluted) | 0.87 | 0.84 | 1.18 | 1.11 | 0.92 | Upgrade
|
| EPS Growth | 3.57% | -28.81% | 6.47% | 20.90% | -4.17% | Upgrade
|
| Free Cash Flow | 94.43 | 43.05 | 6.14 | -45.79 | -28.24 | Upgrade
|
| Free Cash Flow Per Share | 0.50 | 0.23 | 0.03 | -0.24 | -0.15 | Upgrade
|
| Dividend Per Share | - | 0.500 | 0.417 | 0.321 | 0.345 | Upgrade
|
| Dividend Growth | - | 19.99% | 30.02% | -7.16% | 40.04% | Upgrade
|
| Gross Margin | 64.55% | 68.42% | 50.96% | 37.23% | 39.78% | Upgrade
|
| Operating Margin | 10.70% | 10.01% | 10.83% | 7.55% | 7.58% | Upgrade
|
| Profit Margin | 10.63% | 10.58% | 11.92% | 8.11% | 7.58% | Upgrade
|
| Free Cash Flow Margin | 6.08% | 2.83% | 0.32% | -1.77% | -1.24% | Upgrade
|
| EBITDA | 250.93 | 226.84 | 241.56 | 220.72 | 199.92 | Upgrade
|
| EBITDA Margin | 16.15% | 14.94% | 12.71% | 8.56% | 8.79% | Upgrade
|
| D&A For EBITDA | 84.63 | 74.91 | 35.71 | 25.94 | 27.55 | Upgrade
|
| EBIT | 166.3 | 151.94 | 205.85 | 194.78 | 172.36 | Upgrade
|
| EBIT Margin | 10.70% | 10.01% | 10.83% | 7.55% | 7.58% | Upgrade
|
| Effective Tax Rate | 10.04% | 11.25% | 9.14% | 12.75% | 11.60% | Upgrade
|
| Revenue as Reported | - | 1,518 | 1,901 | 2,579 | 2,273 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.